Oncology Pulse Masthead

May 2023

Changes ahead in the mix of new oncology agents

  • 80 new oncology drugs have been approved since 2018, with targeted therapy accounting for the bulk of these new drugs
  • 2022 saw fewer approvals than in recent years, but a more diverse set of approaches and MOAs were approved in 2022 and are "on deck" (positive pivotal data) in 2023
  • Implications of the Inflation Reduction Act (IRA) and recent FDA guidance around accelerated approval portend changes to the "fast-to-market" imperative
View as PDF

2023 could see approval of several new MOAs, as well as cell therapy for solid tumors and multiple bispecific T cell engagers

Key Questions for 2023

We'll Be at ASCO!





A few abstracts we'll be watching...


« Back to Pulse List

Pulses are our e-newsletters that look at recent trends and promising directions across life sciences. Add your name to our mail list to receive future updates.